Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — ASX Small and Mid-Cap Conference 2020
20 slides from Imricor Medical Systems's conference presentation, Sep 7, 2020
Slide 1: ASX Small and Mid-Cap Conference
For personal use only ASX Small and Mid-Cap Conference 10 September 2020
Slide 2: Disclaimer
Disclaimer The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities. For personal use only The information is supplied in summary form and is therefore not necessarily complete. It is not intended that
Slide 3: A pioneer and global leader in developing MRI-guided cardiac ablation products
A pioneer and global leader in developing MRI-guided cardiac ablation products Imricor is an innovative US based medical device company and is the only company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market For personal use only 3 A
Slide 4: An overview of Imricor
An overview of Imricor For personal use only Founder-led business with deep The world’s first commercially available med-tech experience management MRI compatible catheter ablation devices team Large addressable market, Strong IP portfolio and growing to over $4bn1 by patent protection 2022, with fa
Slide 5: Our journey to commercial launch in 2020 & plans for 2021
Our journey to commercial launch in 2020 & plans for 2021 For personal use only 2006 • Imricor is established 2014 • Performed first human pilot 2019 • Signed joint development agreement with Philips Healthcare study with Active MR Tracking 2007 • Licensed IP from Johns Hopkins 2020 • Received CE ma
Slide 6: Heart arrythmias and conventional treatment options
Heart arrythmias and conventional treatment options In the absence of MRI-compatible catheter ablation devices, physicians have been unable to take advantage of the potential benefits related to MRI guided ablation procedures for treating arrhythmias For personal use only Arrhythmias Conventional Tr
Slide 7: The problems we are trying to solve through MRI guided ablation procedures
The problems we are trying to solve through MRI guided ablation procedures only Procedure Procedure Visualisation Cost Safety effectiveness time use Existing Challenges • X-ray imaging provides • Inability to determine • Repeat procedures can • Conventional 3D mapping • Patient and doctor poor heart
Slide 8: Partnering to deliver success and drive growth
Partnering to deliver success and drive growth Imricor has entered into a number of agreements with market leading organisations to support future iCMR lab adoption For personal use only • Joint development agreement to establish • Joint development agreement to establish • Imricor products included
Slide 9: The product portfolio
The product portfolio Consumable Products Vision-MR Ablation Catheter Vision-MR Dispersive Electrode For personal use only • Received CE mark approval in January 2020 • Ablation catheter CE mark approval with an indication for treating type 1 atrial flutter • Imricor is the exclusive provider CE Mar
Slide 10: Pipeline products under development
Pipeline products under development Consumable Products For personal use only Diagnostic Catheter Steerable Sheath and Transeptal Needle • Aiming for mid-2021 commercial release • Currently in prototype phase (pending approval) • Aiming to be ready for clinical trials in 2021 • Supporting margin imp
Slide 11: A strong intellectual property portfolio
A strong intellectual property portfolio For personal use only 18 issued U.S • Imricor’s IP is relatively new, with the Company’s oldest issued patent expiring in Patents 2030 • In addition to protecting Imricor’s devices and procedures, its patents provide an opportunity for the Company to license
Slide 12: Our business model
Our business model Today Imricor primarily generates revenue from the sale of its capital equipment and consumable products For personal use only REVENUE MODEL Capital Equipment Consumables Other (One-off sale) (Ongoing sales) Advantage-MR EP Vision-MR Ablation Catheter IP Licensing Recorder/Stimula
Slide 13: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers For personal use only Drivers of Global Catheter Ablation Market EU1 and US Cardiac Ablation Market Catheter Sales (USD M) • Increased incidence of card
Slide 14: Core strategies to drive future growth
Core strategies to drive future growth Imricor’s strategy is focused on the two drivers that are key to revenue growth – the number of iCMR labs and the number of procedures performed using Imricor’s consumables in each lab For personal use only Go to market strategies Geographic expansion Expanded
Slide 15: Future acceleration in lab rollout plans underpinned by strong pipeline
Future acceleration in lab rollout plans underpinned by strong pipeline • Dresden: Commenced routine procedures in January 2020, training Centre of Excellence For personal use only 3 sites • Haga: Commenced routine procedures in June 2020 operational • UMC Ams: Commenced routine procedures in June 2
Slide 16: Pipeline growth supported by early clinical success
Pipeline growth supported by early clinical success Early clinical success and excellent physician feedback is driving growing interest in Imricor’s products and the opportunity to establish a new standard of care in the treatment of heart arrythmias, with particular focus on For personal use only e
Slide 17: Our focus for the year ahead
Our focus for the year ahead Imricor’s focus for the balance of 2020 is on continuing to execute a controlled product launch For personal use only throughout the EU while pursuing growth opportunities that position the company strongly into 2021 and onwards • Continued lab roll out with focus on acc
Slide 18: Q&A
Q&A For personal use only 18 ASX Small and Mid-Cap Conference, September 2020
Slide 19: What to learn more about Imricor?
What to learn more about Imricor? Transforming Cardiac Ablation Procedures For personal use only Imricor corporate procedural video https://vimeo.com/438663377 Experience the Future of Cardiac Ablation Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Centre discuss their successes per
Slide 20: Contact information
Contact information For personal use only Investors: Steve Wedan Carrie Barrack Executive Chair, President & CEO Cato & Clive Email: steve.wedan@imricor.com Email: carrie@catoandclive.com Website: https://imricor.com/ Follow us: 20 ASX Small and Mid-Cap Conference, September 2020
Imricor Medical Systems — ASX Small and Mid-Cap Conference 2020 on 6ix